A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
ImmunityBio, Inc.
Exelixis
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Royal Marsden NHS Foundation Trust